Сторінка 1 від 34 результати
FIELD OF THE INVENTION
The inventive subject matter relates to a new use of L-butylphthalide in the prevention and treatment of cerebral ischemia-induced diseases, particularly to a use of L-butylphthalide in manufacturing the medicaments for the prevention and treatment of cerebral ischemia-induced
FIELD OF THE INVENTION
The disclosure generally relates to the field of Neurology. More particularly, it relates to compositions and methods for treat neurological diseases associated with an increase in the permeability of the blood brain barrier (BBB), cerebral edema and/or cell death.
BACKGROUND
BACKGROUND OF THE INVENTION
Stroke remains the third most common cause of death in the industrial world, ranking behind ischemic heart disease and cancer. Strokes are responsible for about 300,000 deaths annually in the United States and about 11,000 deaths annually in Austria. Strokes are also a
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted spirobenzazepines useful as, for example, vasopressin receptor antagonists.
BACKGROUND OF THE INVENTION
Vasopressin is a nonpeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone effects
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists.
BACKGROUND OF THE INVENTION
Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone
FIELD OF THE INVENTION
This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists.
BACKGROUND OF THE INVENTION
Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone
TECHNICAL FIELD
The present invention relates to use of timosaponin BII, in particular the use of timosaponin BII in the preparation of a medicament or product for the prevention and treatment of stroke (apoplexy).
BACKGROUND ART
Stroke (apoplexy) involves sudden loss of neural function due to
The present invention relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof.
More particularly, it relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof, which are adenosine antagonists and possess various pharmaceutical actions
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method for preventing or treating a brain edema, an intracranial hemorrhage (especially a recurrence of an intracranial hemorrhage and so on) and a cerebral infarction, which comprises administering a
TECHNICAL FIELD
The present invention relates to the use of N-acetyl-D-glucosamine and pharmaceutical acceptable salts thereof in the manufacture of a medicament for resisting cardiac and cerebral ischemia as well as oxygen-deficiency.
BACKGROUND ART
The cardiac and cerebral ischemia as well as
TECHNICAL FIELD
The present invention relates to a preventive or therapeutic agent for cerebral stroke comprising an interleukin-8 (IL-8)-binding-inhibition agent as an active ingredient. The present invention also relates to a preventive or therapeutic agent for cerebral edema comprising an
TECHNICAL FIELD
The present invention relates to an agent for protecting central nerve cells and enhancing survival thereof
BACKGROUND ART
Hippocampal neurons have widely been used in the field of the neurophysiology as central nerve cells that can be cultured in laboratories. It has been known that
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to cerebral function improving agents, more specifically, those agents which act by suppressing cerebral edema, protecting cerebral function, activating cerebral metabolism, or reducing the extent of cerebral
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to cerebral function improving agents, more specifically, those agents which act by suppressing cerebral edema, protecting cerebral function, activating cerebral metabolism, or reducing the extent of cerebral
This Application is a 371 of PCT/JP2005/000323, filed Jan. 6, 2005; the disclosure of which is incorporated herein by reference.
DETAILED DESCRIPTION OF THE INVENTION
1. Technical Field
The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is